Growth Factors Regenerate Islet Cells

Developed by Transition Therapeutics, Inc. (Toronto, Canada), the treatment is called Islet Neogenesis Therapy (INT). The treatment is needed because current islet cell availability for transplantation is limited.

"If we can transplant fewer islet cells per patient but can increase the amount of insulin generated, then we could treat significantly more people with diabetes,” said Dr. Tony Cruz, chairman and CEO of Transition.

Transition scientists investigated whether INT was capable of regenerating human islet cells and increasing insulin production in severe combined immunodeficiency (SCID) mice. Human islet cells were implanted into SCID mice and then treated with a short course of INT, which resulted in a five-fold increase in human insulin production.




Related Links:
Transition Therapeutics